In clinical trials, patients using Wegovy lost an average of *20.7% of their body weight and kept it off with ongoing treatment
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
The Role of GLP-1 Receptor Agonists in IBD-Related Surgery and IBD-Related Complications of Inflammatory Bowel Disease Among Patients With Metabolic Comorbidities: A Systematic Review and Meta-Analysis
Byun J-K, Park M, Lee S, Yun JW, Lee J, Kim JS, et al
Addressing Specific Hunger Patterns If a patient experiences intense head hunger or cravings that the GLP-1 is not fully suppressing, the stimulant effect of phentermine might be used to target those specific neurological triggers
Why Foods Suddenly Feel Less Satisfying on GLP-1 Therapy Satisfaction from eating involves multiple brain systems: taste buds send signals, but the brain's reward centers (including the nucleus accumbens and ventral tegmental area) determine whether that taste feels rewarding
